LeukoPrint®
The first-in-class leukemia sWGS CNA test
By evaluating the copy number aberration (CNA) in bone marrow cells and/or circulating cell free DNA (cfDNA) via shallow whole genome sequencing (sWGS), in conjunction with conventional cytogenetics, LeukoPrint® makes leukemia diagnosis, molecular subtyping, prognostic stratification and treatment responds monitoring more precise and comprehensive.
Without culturing cells in vitro
High sensitivity and low failure rate
Automatic readout system
An example of CNA profiling of LeukoPrint® reveals abnormal karyotype at molecular level
LeukoPrint® Karyotyping
Specifications
◉ Indicated subjects：Patients with suspected or confirmed leukemia (MDS/AML/ALL/CLL/MM)
◉ Sample requirement：1-2ml bone marrow or 10ml blood
◉ Result readout：copy number aberration（CNA）
◉ TAT：10 work days
How it works
Pre-test inquiry
Informed consent
Blood-draw
Testing
Analyzing + Interpretation
Reporting
All Posts
×